EUVIMEDEUVIMED entdecken
Crossref

Dual Antiplatelet Therapy or Dual Pathway Inhibition

Shinya Goto iD, Shinichi Goto iD

Thrombosis and Haemostasis · 01.03.2024 · 124 (03) · 274-276

DOI: 10.1055/a-2191-7627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2024. Verfasst von Shinya Goto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Cardiology), Department of General Medicine, Tokai University School of Medicine, Isehara, Japan. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Aspirin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsAspirinHumansClopidogrelDrug Therapy, Combination

Substanzen

Platelet Aggregation InhibitorsAspirinClopidogrel

Autor:innen und Institutionen

  • Department of Medicine (Cardiology), Department of General Medicine, Tokai University School of Medicine, Isehara, Japan.

ORCID-Profile: Shinya Goto, Shinichi Goto

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Agency for Medical Research and Development

Zitieren

APA

Goto, S., & Goto, S. (2024). Dual Antiplatelet Therapy or Dual Pathway Inhibition. Thrombosis and Haemostasis, 124(03), 274-276. https://doi.org/10.1055/a-2191-7627

Vancouver

Goto S, Goto S. Dual Antiplatelet Therapy or Dual Pathway Inhibition. Thrombosis and Haemostasis. 2024;124(03):274-276. doi:10.1055/a-2191-7627

BibTeX
@article{Goto2024,
  author = {Goto, Shinya and Goto, Shinichi},
  title = {Dual Antiplatelet Therapy or Dual Pathway Inhibition},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {03},
  pages = {274--276},
  doi = {10.1055/a-2191-7627}
}
Kostenlos starten →